SPONSOR

Ruijin Hospital

Total Trials

Recruiting

Phases

Phase 1, Phase 2, Phase 2, Phase 1, Phase 3

Conditions studied: Breast Cancer Carotid Atherosclerotic Plaque Diffuse Large B-Cell Lymphoma Chronic Graft Versus Host Disease in Eye Allogeneic Hematopoietic Stem Cell Transplantation Pancreatic Cancer Mature B-Cell Lymphoma Heart Failure Metabolic Cardiovascular Syndrome Metabolic Diseases

Ruijin Hospital is a clinical research sponsor with 26 registered studies on ClinicalTrials.gov, of which 26 are actively recruiting participants. Research covers conditions including Breast Cancer, Carotid Atherosclerotic Plaque, Diffuse Large B-Cell Lymphoma, Chronic Graft Versus Host Disease in Eye.

The trial portfolio spans Phase 1, Phase 2, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Ruijin Hospital

How many clinical trials has Ruijin Hospital sponsored?

ClinicalMetric currently tracks 26 clinical trials sponsored by Ruijin Hospital, of which 26 are actively recruiting participants. These trials cover conditions including Breast Cancer, Carotid Atherosclerotic Plaque, Diffuse Large B-Cell Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Ruijin Hospital research focus on?

Ruijin Hospital clinical trials span Breast Cancer, Carotid Atherosclerotic Plaque, Diffuse Large B-Cell Lymphoma, Chronic Graft Versus Host Disease in Eye, Allogeneic Hematopoietic Stem Cell Transplantation, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Ruijin Hospital clinical trial?

To participate in a Ruijin Hospital trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Ruijin Hospital trials with current recruitment status updated daily.

Ruijin Hospital

Frequently Asked Questions — Ruijin Hospital

Clinical Trials by Ruijin Hospital

Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer

Prospective Management of Plaque Instability With Statins and Extra Folic Acid

PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

Observational Cohort Study on Ocular Chronic Graft-Versus-Host Disease

Allogeneic Hematopoietic Stem Cell Transplantation Cohort Study

HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Cell Free DNA in Mature B-cell Lymphoma

Cardiometabolic evalUation REgistry of Heart Failure

Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - III

Adjuvant Pancreatic Therapy Guided by MRD

Ultra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast Cancer

Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study

Bronchoscopic Navigation Robot-guided Dye Marking-assisted Thoracoscopic Pulmonary Nodule Resection

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies

Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer

Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients

Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection

Retrograde Ascending Dissection: Intraluminal Aortic Therapy

Testing if PDR-001 Can Safely and Effectively Remove Harmful Brain Protein in Parkinson's Disease

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses

Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer

a Feasibility Study of iHD-SRT for BM